CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025

Rhea-AI Summary

CorMedix (Nasdaq: CRMD) will report third-quarter 2025 financial results for the period ended September 30, 2025, before the market opens on November 12, 2025, and will host a corporate update conference call at 8:30 AM ET that day.

The company is commercializing DefenCath for prevention of catheter-related bloodstream infections in adult hemodialysis patients and, following its August 2025 acquisition of Melinta Therapeutics, is commercializing a portfolio of anti-infective products (including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, KIMYRSA) and TOPROL-XL.

CorMedix has ongoing DefenCath studies in total parenteral nutrition and pediatric populations, and REZZAYO has an ongoing Phase III prophylaxis study with topline results expected in Q2 2026.

Positive

• Acquisition completed in August 2025 expands anti-infective portfolio
• Commercializing DefenCath for catheter-related bloodstream infection prevention
• REZZAYO approved for candidemia and invasive candidiasis in adults
• REZZAYO Phase III topline results expected in Q2 2026

Negative

• None.

Insights

Biotech Commercial & Clinical Analyst

Upcoming earnings call plus recent acquisition and a Phase III topline date create measurable near‑term milestones, but no new financial data yet.

CorMedix will report results for the quarter ended September 30, 2025 and host a conference call on November 12, 2025. The company is commercializing DefenCath and, after its August 2025 acquisition of Melinta Therapeutics LLC, a portfolio that includes MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, KIMYRSA, and TOPROL-XL. These facts describe revenue drivers but do not disclose financial metrics in this release.

The material near-term dependency is the company’s upcoming financial report, which will reveal sales, margins, and acquisition-related costs. Another defined milestone is topline results for the Phase III REZZAYO prophylaxis study expected in Q2 2026. Key items to watch are the November 12 earnings figures and any commentary on Melinta integration, product-level sales, and the REZZAYO trial timeline; those items will clarify commercial traction and near-term cash impacts within months.

BERKELEY HEIGHTS, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the third quarter ended September 30, 2025, before the market opens on Wednesday, November 12, 2025, and will host a corporate update conference call at 8:30am Eastern Time.

Wednesday, November 12th @ 8:30am ET
Domestic:	1-844-676-2922
International:	1-412-634-6840
Webcast:	Webcast Link

About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. CorMedix is commercializing DefenCath^® (taurolidine and heparin) for the prevention of catheter-related bloodstream infections in adult patients undergoing hemodialysis via a central venous catheter. Following its August 2025 acquisition of Melinta Therapeutics LLC, CorMedix is also commercializing a portfolio of anti-infective products, including MINOCIN^® (minocycline), REZZAYO^® (rezafungin), VABOMERE^® (meropenem and vaborbactam), ORBACTIV™ (oritavancin), BAXDELA^® (delafloxacin), and KIMYRSA^® (oritavancin), as well as TOPROL-XL^® (metoprolol succinate).

CorMedix has ongoing clinical studies for DefenCath in Total Parenteral Nutrition and Pediatric patient populations and also intends to develop DefenCath as a catheter lock solution for use in other patient populations. REZZAYO is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of IFD in adult patients undergoing allogeneic BMT. Topline results of the Phase III study for REZZAYO are expected in Q2 2026. For more information visit: www.cormedix.com or www.melinta.com.

Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576

FAQ

When will CorMedix (CRMD) report Q3 2025 results and hold its investor call?

CorMedix will report Q3 2025 results before market open and host a call on November 12, 2025 at 8:30 AM ET.

What products did CorMedix add with the August 2025 Melinta acquisition (CRMD)?

The acquisition added anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, KIMYRSA and TOPROL-XL.

What is DefenCath and which patients is CorMedix (CRMD) commercializing it for?

DefenCath is a taurolidine-heparin catheter lock; CorMedix is commercializing it to prevent catheter-related bloodstream infections in adult hemodialysis patients.

When does CorMedix expect REZZAYO Phase III topline results and for what indication?

Topline results for the REZZAYO Phase III prophylaxis study in adult allogeneic BMT patients are expected in Q2 2026.

How can investors join the CorMedix (CRMD) November 12, 2025 webcast and call?

Investors can join via the domestic dial-in 1-844-676-2922, international 1-412-634-6840, or the company webcast link provided for the Nov 12 call.